Abstract
Chemotherapy has remained the major treatment modality for patients with metastatic or recurrent colorectal carcinoma. The chemotherapeutic agent, 5-fluorouracil (FUra), has been the “standard” therapy for a number of years. The objective response rate for this single agent has been disappointing with most series reporting response rates between 12 and 20%. Recent studies involving intracellular pharmacokinetics of FUra have provided information concerning mechanisms which lead to cellular resistance to the active metabolite, FdUMP, which binds to intracellular thymidylate synthetase (TS). A number of recent studies have now been performed which suggest that increased levels of intracellular reduced folate analogs can overcome intracellular drug resistance to FdUMP.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J. Grem, D. Hoth, J.M. Hamilton, Overview of current status and future directions of clinical trials with 5-fluorouracil in combination with folinic acid, Cancer Treat. Rep. 12: 1249–1264 (1987).
J.D. Hines, M. Zakem, D.J. Adelstein, et al, Treatment of advanced stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: A Pilot Study, J. Clin Oncol. 6: 142–146 (1988).
J.A. Straw, D. Szapary, W.T. Wynn, Pharmacokinetcis of the diastereo isomers of leucovorin after intravenous and oral administration to normal subjects, Cancer Res. 44: 3114–3119 (1984).
J.D. Hines, M. Zakem, D.J. Adelstein, et al, Bioavailability of high-dose oral leucovorin, Development of folates and folate antagonists in cancer chemotherapy, N.C.I. Monographs 5: 57–60 (1987).
H.W. Bruckner, T. Ohnuma, R. Hart, et al, Leucovorin potentiation of 5-fluorouracil, efficacy and potency, Proc. Assoc. Cancer Res. 23: 434 (1982).
H.W. Bruckner, J. Roboz, M. Spiegelman, et al, An efficient leucovorin and 5-fluorouracil sequence dosage escalation and pharmacologic monitoring, Proc. Am. Assoc. Cancer Res. 24: 547 (1982).
D. Machover, E. Goldschmidt, P. Chollet, et al, Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high-dose folinic acid. J. Clin. Oncol. 4: 685–696 (1986).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Plenum Press, New York
About this chapter
Cite this chapter
Hines, J.D., Adelstein, D.J., Spiess, J.L., Carter, S.G., Trey, J.E. (1988). High-Dose Weekly Oral Leucovorin and 5-Fluorouracil in Previously Untreated Patients with Advanced Colorectal Carcinoma: A Phase I Study. In: Rustum, Y., McGuire, J.J. (eds) The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy. Advances in Experimental Medicine and Biology, vol 244. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-5607-3_17
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5607-3_17
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4684-5609-7
Online ISBN: 978-1-4684-5607-3
eBook Packages: Springer Book Archive